Lumipulse® G 25-OH Vitamin D

New "ray of light" in Vitamin D testing

Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency.

 

CE marked (IVDR)
Lumipulse® G 25-OH Vitamin D Immunoreaction Cartridges

Product number 234013

3 x 14 Tests
Lumipulse® G 25-OH Vitamin D Calibrators

Product number 234020

1 x 6 x 1.5 ml
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Details
  • Citations
  • Documentation
  • Related products
  • Details

    Advantages & Features

    • Sandwich assay - showing improved performance
    • Improved equimolarity - 25-OH Vitamin D2 and D3
    • Higher correlation with LC-MS/MS
    • A broad dynamic assay range - 4,0-150 ng/mL
    • Novel VDBP release, no manual steps or auxilliary reagents required
    • Good precision - within run 0,7-2,2% and total precision 1,6-3,5%
    • 25 minute assay time, with a real throughput of 120 tests/hour combined with other analytes
    • 30 day calibration
    • Individual cartridge concept

     

    Clinical background

    Vitamin D is a fat-soluble, secosteroid hormone precursor. In humans, the most abundant forms are Vitamin D3 (cholecalciferol), followed by Vitamin D2 (ergocalciferol), known together as calciferol. Calciferol primarily undergoes hydroxylation in the liver to 25-OH Vitamin D (calcidiol), the major circulating form of vitamin D. The serum or plasma level of 25-OH Vitamin D is recognized as the most reliable indicator of vitamin D sufficiency.  A second hydroxylation in the kidneys of a small amount of 25-OH Vitamin D produces 1,25(OH)2 Vitamin D (calcitriol).  Calcitriol regulates calcium and phosphate blood concentrations through amongst other intestinal absorption.

    Did you know?
    Low 25-OH Vitamin D serum levels (lower than 10 ng/ml) have been found in 2-30% of adults within the European population [1]

    Vitamin D deficiency was first discovered in the childhood disease rickets. However due to recent trends to avoid prolonged sun exposure due to cancer and aging impacts, the world's population is even more at risk. Deficiency has been linked to various other medical conditions other than bone metabolism such as: adult osteomalacia, incresed risk for fractures, secondary hyperparathyroidism, autoimmune diseases, diabetes, associated with increased risk for certain cancers, and cardiovascular problems.

     
    References

    1. International Osteroporosis Foundation.

    2. WHO Scientific Group on the Prevention and Management of Osteoporosis 2003 Prevention and management of osteoporosis: report of a WHO scientific group. Geneva: World Health Organization.

    3. Holick MF et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab. 2011; 96: 1911-1930.

     

    See the LUMIPULSE G1200 working in this video:

     

  • Citations

    The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.